Gonadostatin

• US 4,409,139 A
• Filed: 08/10/1981
• Issued: 10/11/1983
• Est. Priority Date: 08/10/1981
• Status: Expired due to Fees

• Current Assignee: Salk Institute for Biological Studies
• Original Assignee: Salk Institute for Biological Studies
• Inventors: Ying, Shao-Yao, Ling, Nicholas C., Esch, Frederick S., Guillemin, Roger C. L.
• Primary Examiner(s): Lieberman, Allan
• Assistant Examiner(s): Short, Patricia
• Application Number:
  US06/291,294
• Time in Patent Office: 792 Days
• Field of Search: 424/105, 260/112 R, 260/112.5 LH
• US Class Current: 530/313
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695

Abstract

A substantially purified substance has been isolated from bovine gonadal secretions which mediates pituitary hormone secretion, using an extraction and purification sequence that includes gel filtration, partition chromatography and HPLC in that order. The substance, designated gonadostatin, is a moderate-size peptide which below a threshold level selectively inhibits LRF-stimulated pituitary secretion of LH and FSH. Above a threshold level, gonadostatin generally stimulates pituitary hormone secretion.

Claims

1. A method of deriving substantially pure gonadostatin, a proteinaceous mammalian gonadal substance characterized by its selective inhibition of LRF-stimulated pituitary secretions of LH and FSH in dosages below a threshold level and general stimulation of pituitary hormone secretion in dosages above a threshold level, the method comprising:

obtaining a mammalian gonadal secretion;

initially separating the components of said secretion according to molecular weight by gel filtration and obtaining a partially purified material containing eluate fractions which deomonstrate gonadostatin activity;

further separating components of said partially purified material by partition chromatography with a two-phase 1-butanol, pyridine, acetic acid, water eluent system to obtain further purified material; and

additionally purifying said further purified material by reverse phase high performance liquid chromatography with a formic acid, pyridine, 1-propanol, water eluent system of increasing 1-propanol concentration to obtain a substantially purified substance which demonstrates activity in inhibiting the LRF-stimulated secretion of LH and FSH by the pituitary.

2. A method according to claim 1 wherein said gel filtration eluent fractions are selected for containing material having molecular weights of approximately 10,000 to 12,000 as determined by gel filtration.

3. A method according to claim 1 wherein the step of partition chromatography comprises:

forming a two-phase eluent system of 1-butanol, pyridine, acetic acid and water;

packing a column of highly cross-linked polysaccharide support material and equilibrating said support material with the lower phase of said eluent system; and

eluting said partially purified material with the upper phase of said eluent system.

4. A method according to claim 1 wherein said eluent system comprises 1-butanol, pyridine, acetic acid and water in about a 6:

6;

1.2;

4.8 ratio.

5. A proteinaceous mammalian gonadal substance derived by the method of claim 1, said substance characterized as having a molecular weight of approximately 10,000 to 12,000, as determined by gel filtration, and by its selective inhibition of LRF-stimulated pituitary secretions of LH and FSH in dosages below a threshold level and general stimulation of pituitary hormone secretion in dosages above a threshold level.